NICE modulator appraisal - January 31 update

News -

Today our Chief Executive reflects on the latest update on the NICE appraisal.

NICE have confirmed today that they are pausing their appraisal process, which allows time for commercial negotiations to take place. We now need Vertex to confirm that they will start this process and work to bring an end to the uncertainty, ensuring access now and in the future for everyone who can benefit from these medicines. It’s important to reiterate that the NHS and NICE have confirmed that access is protected for those already taking the medicines and for anyone starting while discussions continue.

David Ramsden, Chief Executive of Cystic Fibrosis Trust

You can read more about the NICE appraisal on our website here

Read the statement from NICE here

We’ll continue to keep the CF community informed as the appraisal progresses, and we won’t stop working to make sure that everyone with CF have the treatments they need to live a long and healthy life.

If you’re feeling anxious or worried, please contact our Helpline.  

Call 0300 373 1000 or 020 3795 2184, Monday–Friday 10am–4pm 

Email [email protected] 

Chat with us on Facebook, Twitter or Instagram 

Message us on WhatsApp on 07361 582053 

Related content

NICE appraisal of modulator therapies

Blog -

Part of the NHS deals to grant access to modulator therapies included the agreement that data would be collected on their effectiveness. With the period of data collection ending in 2023, NICE is soon to embark on an appraisal of modulator therapies. Cystic Fibrosis Trust has provided feedback to the NICE consultation on how to approach this appraisal.

An update on the NICE appraisal of Orkambi, Symkevi and Kaftrio

Blog -

In October, NICE’s independent committee will meet to discuss Orkambi, Symkevi and Kaftrio and make recommendations on whether these treatments should be available on the NHS for people with CF who are not currently taking a modulator therapy, but who could benefit from them in the future. 

Reflections on the MHRA announcement and NICE process

News -

Today, our Chief Executive reflects on the past week of cystic fibrosis news: from NICE’s draft recommendations on modulator therapies Orkambi, Symkevi and Kaftrio, to yesterday’s announcement that children aged 2–5 years old have been approved to use Kaftrio.  

Your donation will make a difference: